Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for Medically Refractory Pouchitis
NCT05578508Phase 1Withdrawn
- Sponsor
- Cleveland Clinic
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in pouchitis, sponsored by Cleveland Clinic. Primary endpoints: Adverse Events at 12 months and Healing at 12 months. Planned start Apr 2022; status: withdrawn.
02
Drugs
mesenchymal stem cells
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT05578508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578508.